back to News & Blog

Evid Science Receives Seed Capital to Advance Clinical AI Platform

LOS ANGELES, CA (February 15, 2018) – Evid Science, an artificial intelligence (AI) company for the pharmaceutical industry, has successfully secured seed funding from TKS I, a new private equity fund dedicated to early stage life science companies.

“Our technology is quite advanced,” says Dr. Matthew Michelson, CEO of Evid Science. “Within seconds, the platform is able to answer questions about how effectively a given drug performs within its class, or how the safety profiles of two competing therapies stack up to one another. This new funding will help us drive our product to market and into the hands of pharmaceutical researchers, medical affairs personnel and marketers. We are thrilled to have TKS I on board who share both our short and long-term visions.”

Read the Full News Article